Browsing by Author "Sequeira, J"
Now showing 1 - 10 of 10
Results Per Page
Sort Options
- Bronquiolite: Avanços RecentesPublication . Baptista, M; Sequeira, JA bronquiolite e a infecção respiratória aguda das vias aéreas inferiores mais frequente em criançascom idade inferior a 24 meses, responsável por morbimortalidade significativa, incluindo complicações frequentes na fase aguda e a longo prazo. A heterogeneidade da abordagem desta patologia e a dificuldade em reduzir o seu peso nos indices de saúde pública, vem motivando investigação contínua e legitimou a publicação recente (2006) pela Academia Americana de Pediatria (AAP) de normas de actuação, chamando-se a atenção para os resultados de uma metanálise realizada pela Cochrane Collaboration e para a existência de diversos fenotipos de apresentação c1ínica.Os autores abordam alguns aspectos epidemiológicos, c1ínicos (nomeadamente as complicações) e, sobretudo, de terapêutica, com base em estudos recentes, elaborando uma proposta concretade actuação.
- Influence of Weather on Seizure Frequency - Clinical Experience in the Emergency Room of a Tertiary HospitalPublication . Brás, P; Barros, A; Vaz, S; Sequeira, J; Melancia, D; Fernandes, A; de Sousa, A; Dias, S; Menezes Cordeiro, I; Manita, M
- Intoxicação por Organofosforados. Avaliação Prognóstica em 143 DoentesPublication . Sequeira, J; André, P; Miranda, H; Sá, J
- Memorial da Serralharia - Arqueologia do Passado Recente no Hospital de São JoséPublication . Sequeira, J; Boavida, C; Leão, AEste artigo é um contributo para a memória operária da cidade de Lisboa a partir da identificação e levantamento de uma serralharia em risco de colapso no espaço do Hospital de São José. Situada numa área com necessidade de recuperação, a serralharia periclitante pela passagem das décadas, ainda alberga maquinaria industrial e é uma oficina de recurso para além de espaço de armazenamento de materiais. Estando no horizonte, por questões de segurança, a eventual demolição do imóvel, os autores uniram esforços para preservar a memória histórica, antropológica, arqueológica e etnográfica de um edifício que no fundo reco lhe reacções silenciosas e momentos de ponderação e reflexão quando é mencionado este facto: José Saramago trabalhou aqui.
- Parvovirus B19 Infection Associated with Hemolytic Anemia and Cranial PolyneuropathyPublication . Sequeira, J; Calado, A; Dias, M; Manita, MParvovirus B19 (PB19) is a common, widespread, small, single-stranded DNA virus which has been linked with a broad spectrum of clinical illnesses, including a variety of neurological complications such as encephalitis, meningitis, myelitis, stroke, cerebellar ataxia, and neuropathy. The authors describe a case of PB19 infection associated with hemolytic anemia and cranial polyneuropathy involving the second and third cranial nerves in a 23-year-old immunocompetent woman. The diagnosis of acute PB19 infection was established with detection of positive DNA and anti-PB19 IgM antibodies in blood samples. Antiganglioside antibody studies were performed and serum anti-GD1b IgG was strongly positive. Further investigation was normal or negative, excluding other infectious or autoimmune disorders. The patient was initially treated with a 5-day course of intravenous immunoglobulin (IGIV). Because of incomplete neurological recovery, methylprednisolone was also administered 7 days after IGIV therapy initiation. Complete resolution of clinical symptoms was observed 3 months after disease onset at follow-up visit, despite the persistence of PB19 DNA and anti-PB19 IgM antibodies in serum 5 months after the initial presentation. Our report provides evidence that PB19 could affect both the central and peripheral nervous system, possibly by triggering an autoimmune mechanism that leads to autoantibody production.
- Postinfectious Anti-Myelin Oligodendrocyte Glycoprotein Antibody Positive Optic Neuritis and MyelitisPublication . Vieira, JP; Sequeira, J; Brito, MJWe report the case of a 9-year-old girl admitted with fever, headache, and a cerebrospinal fluid lymphocytic pleocytosis. Polymerase chain reaction was positive for human herpes virus 6. She subsequently developed ataxia and bilateral loss of vision. Magnetic resonance imaging (MRI) showed bilateral optic nerve lesions with extension to optic chiasm and a short-segment myelitis. Serologic studies were positive for Borrelia burgdorferi IgM. Anti-aquaporin 4 antibody was negative and anti-myelin oligodendrocyte glycoprotein antibody (MOG) positive. After intravenous methylprednisolone, ceftriaxone, and intravenous immunoglobulin, her vision slowly recovered. The patient was discharged with only mild visual acuity loss, 1 month after admission. Brain MRI was repeated later and was normal and MOG assay became negative. In our view, this patient suffered from a postinfectious, anti-MOG-mediated, spinal cord and optic nerve demyelination.
- Real-Word Effectiveness and Safety of Dimethyl Fumarate in a Multiple Sclerosis Portuguese PopulationPublication . Barros, A; Sequeira, J; Sousa, A; Parra, J; Brum, M; Pedrosa, R; Capela, CObjectives: The aim of this study was to evaluate postmarketing dimethyl fumarate (DMF) safety and effectiveness in a real-world population with relapsing-remitting multiple sclerosis (RRMS). Methods: This was a retrospective, single-center study with RRMS patients treated with DMF. Demographic, clinical, and imagiological characteristics were analyzed, including annualized relapse rate (ARR), Expanded Disability Status Scale, "No Evidence of Disease Activity 3," previous treatment, adverse events, treatment duration, and reason for discontinuation. We investigated which baseline variables were associated with clinical and radiological outcomes. Results: We included 176 patients (70.4% females) with a median on-treatment follow-up time of 25.5 months. In total, 139 patients received prior disease-modifying therapies, and 37 were treatment-naive. Annualized relapse rate decreased by 77.1% in the total population (P < 0.001) and also decreased in the naive, tolerability switch, and efficacy switch groups by 95.8%, 56.7%, and 76.6% (P < 0.001). No Evidence of Disease Activity 3 status after 12 months of DMF treatment was maintained in 69.2% patients. Thirty patients (17%) discontinued treatment because of adverse drug reactions, and 21 (11.9%) because of lack of effectiveness. The occurrence of first relapse during follow-up was associated with higher ARR in the year before DMF start (hazard ratio, 4.833; P < 0.001) and prior exposure to multiple sclerosis treatments (tolerability and efficacy switchers). Conclusions: In this real-world audit, DMF appeared to be effective and safe for RRMS. Additionally, the study suggested that naive patients strongly benefit from DMF, and DMF also improves ARR in patients who switched from injectable therapies due to tolerability and efficacy issues.
- REALMS Study: Real-World Effectiveness and Safety of Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis in PortugalPublication . Batista, S; Nunes, CC; Cerqueira, JJ; Martins Silva, A; Correia de Sá, J; Ferreira, J; Mendonça, MT; Pinheiro, J; Salgado, V; Correia, AS; Sequeira, J; Costa, A; Sousa, LBackground: Fingolimod, an oral sphingosine 1-phosphate receptor modulator, is approved by EMA for relapsing-remitting multiple sclerosis (RRMS). Objectives: To assess the effectiveness and safety of fingolimod in patients with RRMS in real-world clinical practice in Portugal. Methods: Retrospective, multicentre, non-interventional study, reporting 3 years follow-up of data collected from October 2015 to July 2016. Sociodemographic data and previous treatments at baseline and data regarding disease evolution, including number of relapses, annualised relapse rates (ARR) and Expanded Disability Status Scale (EDSS), were collected. Results: Two-hundred and seventy-five participants were enrolled in the REALMS study. Results showed that the main reason to switch to fingolimod was failure of previous treatment (56.7%) and only 3.6% were naïve patients. In the total population, there was a significant decrease in ARR of 64.6% in the first year of treatment, 79.7% in the second year and 82.3% in the third year, compared with baseline. More than 67.0% of patients had no relapses during the 3 years after switching to fingolimod. EDSS remained stable throughout the study. Conclusions: Therapy with fingolimod showed a sustained effectiveness and safety over the 3 years, particularly on patients switched from first-line drugs (BRACE). No new safety issues were reported.
- Seroconversion Rate Following HBV Vaccination in Clinical Practice: The Role of Age and DMT TreatmentPublication . Faustino, P; Coutinho, M; Leitão, L; Capela, C; Brum, M; Parra, J; Sequeira, J; Barros, A; Araújo, C; Sousa, A; Ladeira, FHBV screening and immunization is recommended in all MS patients and is mandatory before the start of some DMT. However, studies evaluating the immune response to HBV vaccine in MS patients are scarce. We aimed to evaluate the seroprotection rate following HBV immunization in MS patients and to assess if older age and DMT-treatment influenced seroprotection. We conducted a cohort study between 2016 and 2020 and compared the immune response to HBV vaccine in MS patients under different DMTs and in patients 50 years old or younger and older than 50. We found that patients under non-injectable DMT presented lower rates of seroprotection comparing to patients under injectable DMT's or without treatment. In patients older than 50, although the seroprotection rate was similar to the remaining patients, the antibody anti-HBV surface antigen titers following HBV immunization were lower and patients were more likely to require a 4th dose of the vaccine to achieve seroprotection. Our findings highlight to need to consider HBV immunization in MS patients early in the disease course, in order to ensure a proper immune response to the vaccine.
- Spastic Paraparesis and Sensorineural Hearing Loss: Keep Brucellosis in MindPublication . Dias, S; Sequeira, J; Almeida, M